On Sept. 4, 2026, Novartis announced that its late-stage clinical study evaluating pelacarsen didn't meet its primary endpoint of reducing the risk of cardiovascular events compared to placebo.

Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS ...

Novartis struck the deal to license the messenger RNA drug candidate and gain options over future therapies.

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular ...

Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death ...

The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.

Oct 7 (Reuters) - The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic ...

Novartis has come under increasing pressure after a series of clinical and pipeline setbacks in the second half of 2026, culminating in calls from a major shareholder for changes to the company's ...

Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a precaution ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...

Abogen Biosciences has entered into a licensing and option agreement with Novartis covering ABO2203 and additional potential ...

Morrisville expects $12.6 million in tax revenue over eight years but has lowered wage and taxable-value requirements.